The HSE expert drugs group meets on Tuesday to discuss whether the weight loss drug Mounjaro should be publicly reimbursed, a decision consultant endocrinologist Professor Donal O’Shea tells RTÉ.ie could be “transformative” for the State while potentially costing between €2 billion and €3 billion over five years. That projected state expenditure sits against a total national drugs budget slated to top €4 billion next year, according to figures reported by The Irish Times.
Expert Group Weighs Mounjaro Reimbursement Decision
The HSE expert drugs group gathers on Tuesday to evaluate the clinical benefits of tirzepatide, widely known as Mounjaro and manufactured by Eli Lilly, to determine if patients can receive it free or at a reduced cost. RTÉ.ie reports that the pharmaceutical company has engaged with Irish authorities in recent months regarding a pricing offer. The National Centre for Pharmacoeconomics (NCPE) stated in December that the drug was not cost-effective at initial pricing, but noted the HSE should consider reimbursement if a price reduction was agreed with the manufacturer. Professor Michael Barry of the NCPE stated in June, as reported by The Irish Times, that Eli Lilly made a significant price reduction offer bringing the drug close to cost-effectiveness, though state costs would still reach multi-billion euro figures.
Clinical Criteria and Projected Patient Eligibility
More than one million people are likely to be eligible for the treatment if approved, according to Professor Donal O’Shea via RTÉ.ie. Patients must meet strict clinical criteria agreed upon by clinicians, evaluated through factors such as body mass index (BMI), obesity-related co-morbidities, lifestyle, and diet. Professor Carel le Roux, professor of metabolic medicine at UCD, noted in RTÉ.ie coverage that international randomised controlled trials demonstrate reductions in heart attack risks and the potential to put type 2 diabetes patients into glycemic remission. The Irish Times notes that the Health Products Regulatory Authority recorded over 1,500 reports of suspected adverse reactions from weight-loss medications since 2023.
Current Access Costs Under the Irish Health System
Saxenda remains the only daily-injected GLP-1 therapy reimbursed for weight loss by the HSE, making it free under medical cards or subsidised via the Drugs Payment Scheme at a €80 monthly limit, as detailed by The Irish Times. Meanwhile, Ozempic is supplied free to over 45,000 people under the Long-Term Illness Scheme and to 8,348 individuals via medical cards strictly for type 2 diabetes treatment. Patients purchasing Ozempic privately for weight loss pay in excess of €200 a month outside public reimbursement schemes, as confirmed by The Irish Times.
Frequently Asked Questions About Weight Loss Drug Access
How does the NCPE determine if a drug is cost-effective for the HSE?
The National Centre for Pharmacoeconomics evaluates clinical evidence supporting a drug’s efficacy, its overall product cost, and the financial impact on patients before issuing recommendations to the HSE drugs group, as outlined by The Irish Times.
What active ingredients differentiate Mounjaro from Ozempic and Wegovy?
Mounjaro uses the active ingredient tirzepatide and is manufactured by Eli Lilly, whereas Ozempic and Wegovy use semaglutide and are produced by Novo Nordisk, according to The Irish Times.
What budget announcement coincided with the upcoming drug review?
Minister Jennifer Murnane O’Connor announced €2.4 million in Budget 2027 alongside additional posts dedicated to expanding obesity services, which Professor Donal O’Shea described to RTÉ.ie as a major advancement for metabolic care.
Keep reading